Samrat Pharmachem (BOM:530125) Other Stockholders Equity: ₹651 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530125 Samrat Pharmachem Ltd BOM:530125
71 GF Score
Price ₹237.05
GF Value ₹362.28
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Samrat Pharmachem Other Stockholders Equity?

Samrat Pharmachem BOM:530125 +0.30% 71 Other Stockholders Equity is ₹651 Mil as of Mar. 2026. GuruFocus rates BOM:530125 with a GF Score™ of 71/100 and a GF Value™ of ₹362.28 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Samrat Pharmachem's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹651 Mil.

Samrat Pharmachem's quarterly Other Stockholders Equity declined from Sep. 2025 (₹676 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹651 Mil).

Samrat Pharmachem's annual Other Stockholders Equity declined from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹-0 Mil) but then increased from Mar. 2025 (₹-0 Mil) to Mar. 2026 (₹651 Mil).

Samrat Pharmachem Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Samrat Pharmachem's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Samrat Pharmachem Other Stockholders Equity Chart

Samrat Pharmachem Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 0.00 -0.00 650.90

Samrat Pharmachem Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 675.85 0.00 650.90
BOM:530125
71GF Score
Samrat Pharmachem Ltd BOM:530125
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Samrat Pharmachem Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹651 Mil mean?
Samrat Pharmachem (BOM:530125) has a Other Stockholders Equity of ₹651 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Samrat Pharmachem and its competitors.
Is Samrat Pharmachem's Other Stockholders Equity too high?
Samrat Pharmachem's current Other Stockholders Equity is ₹651 Mil. Overall, Samrat Pharmachem has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's Other Stockholders Equity compare to DOW?
Samrat Pharmachem's Other Stockholders Equity of ₹651 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Chemicals company?
A good Other Stockholders Equity depends on the Chemicals industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Samrat Pharmachem and its competitors. Samrat Pharmachem's current Other Stockholders Equity is ₹651 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹362.28, compared to a current price of ₹237.05 — trading 34.6% below its estimated fair value. The current Other Stockholders Equity is ₹651 Mil. Samrat Pharmachem's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current Other Stockholders Equity is ₹651 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?

Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued. The current stock price of ₹237.05 is trading 34.6% below its estimated GF Value™ of ₹362.28. GuruFocus considers Samrat Pharmachem to be Significantly Undervalued.

Key valuation signals for BOM:530125:

  • Other Stockholders Equity: ₹651 Mil
  • GF Value™: ₹362.28 vs. price of ₹237.05 (34.6% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Samrat Pharmachem Business Description

Address M. A. Road, 701/702, Business Square, Andheri (West), Mumbai, MH, IND, 400 058
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
71GF Score

Get the complete analysis for BOM:530125

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹237.05
Price
₹362.28
GF Value